BioXcel Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
BioXcel Therapeutics, Inc. (BTAI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-03-28
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -0.60%, a 300.00% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.30%.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.40%, a 500.00% decline from fiscal 2021.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was 0.10%, a 88.89% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | -0.60% 10-K · filed 2025-03-28 |
| 2023-12-31 | 0.30% 10-K · filed 2025-03-28 |
| 2022-12-31 | -0.40% 10-K · filed 2024-03-22 |
| 2021-12-31 | 0.10% 10-K · filed 2023-03-16 |
| 2020-12-31 | 0.90% 10-K · filed 2022-03-11 |
| 2019-12-31 | -1.40% 10-K · filed 2021-03-12 |
| 2018-12-31 | -2.20% 10-K · filed 2020-03-09 |
| 2017-12-31 | -4.20% 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |